Cargando…
Targeting the red cell enzyme pyruvate kinase with a small allosteric molecule AG-348 may correct underlying pathology of a glycolytic enzymopathy
Autor principal: | Alayash, Abdu I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776336/ https://www.ncbi.nlm.nih.gov/pubmed/33386714 http://dx.doi.org/10.3324/haematol.2020.266585 |
Ejemplares similares
-
ENZYMOPATHIES
Publicado: (1981) -
AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes
por: Rab, Minke A.E., et al.
Publicado: (2020) -
Optimal Fluxes, Reaction Replaceability, and Response to Enzymopathies in the Human Red Blood Cell
por: De Martino, A., et al.
Publicado: (2010) -
Hereditary Non-Spherocytic Hemolytic Anemia (HNSHA): Four Children with Rare Hereditary Red Cell Enzymopathies
por: Sivasankaran, Meena, et al.
Publicado: (2021) -
Predicting the impact of diet and enzymopathies on human small intestinal epithelial cells
por: Sahoo, Swagatika, et al.
Publicado: (2013)